Epix makes progress in US with Vasovist trial
This article was originally published in Clinica
Executive Summary
After numerous stumbling blocks, things are looking up for Epix as the US FDA has authorised a protocol for the re-analysis of trial results that is key to the approval of its Vasovist imaging agent. The company should now be firmly on the path to gaining approval by the end of 2008, company spokesperson Keri Mattox told Clinica.